Novo Nordisk, FDA

Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.
US FDA says lowest dose of Novo Nordisk's weight-loss drug now available
The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available on the U.S. health regulator's website on Wednesday. Several doses of Novo's GLP-1 therapies such as Wegovy and diabetes drug Ozempic,
Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,
FDA says all ver­sions of Novo's GLP-1 weight loss drugs are now avail­able
The FDA on Wednesday updated its drug shortage database to say that all dosages and versions of Novo Nordisk's Wegovy and Ozempic are
FDA posts summary of Novo Nordisk site inspections made earlier this year
The FDA has posted a summary of Novo Nordisk (NVO) site inspections made over several dates in March of this year at the company’s Drug
Key Novo Nordisk plant where Wegovy, Ozempic made cited by FDA
A Novo Nordisk production facility in Denmark where semaglutide, the active ingredient in its weight loss and type 2 diabetes medicines Wegovy and Ozempic, are made was cited for several deficiencies during an FDA site inspection in March.
BioPharma Dive3h
Novo takes big step toward ending Ozempic, Wegovy shortages
All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...
FiercePharma7d
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide
The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo ...
Pharmacists claim “desperation” by Novo Nordisk over semaglutide copycat block
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...
STAT7d
Novo asks FDA to bar compounders from making Ozempic copies
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...